Discussion
A Phase 2 clinical trial testing Lexeo Therapeutics’ gene therapy LX2006 in people with Friedreich’s ataxia (FA) and the heart condition cardiomyopathy expects to enroll its first participant by the end of the month, the company said. The SUNRISE-FA 2 study is a pivotal trial, with data…
